Chronic Urticaria – Current Treatment – Treatment Algorithms: Claims Data Analysis – Chronic Spontaneous Urticaria (US)
The treatment landscape for chronic spontaneous urticaria (CSU) remains largely driven by oral therapies, including approved antihistamines and off-label agents such as DMARDs and immunosuppressants; however, many patients continue to experience inadequate symptom control. Novartis / Roche’s Xolair and Sanofi / Regeneron’s Dupixent (approved in 2025) are currently the only biologics approved for CSU in the United States and are expected to continue to expand their share given the limited availability of fast-acting, highly efficacious alternatives, while the 2025 approval of Novartis’s Rhapsido marks the first targeted oral option. Montelukast is no longer recommended in current CSU treatment guidelines, limiting its role, and the off-label biologic use (TNF inhibitors) highlights the ongoing need for more effective therapies.
Questions answered
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed CSU patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed CSU patients?
- How have the biologics Xolair and Dupixent been integrated into the treatment algorithm, and what is their source of business?
- What percentage of CSU patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of CSU patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
Product description
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall, using real-world, patient-level claims data, enabling you to:
- Understand patient flow between lines of therapy.
- Evaluate your brand share against competitors.
- Accurately assess your source of business.
- Quantify opportunities at different stages of the treatment algorithm.
Markets covered: United States
Key companies: Roche / Novartis, Sanofi / Regeneron, AbbVie, Amgen, Samsung Bioepis, Merck, Sandoz
Key drugs: Xyzal, Zyrtec, Benadryl, Vistaril, Xolair, Dupixent, Allegra
Key analysis provided: Brand / therapy usage across longitudinal patient sample, newly diagnosed patient analysis, treatment initiation and progression, line of therapy analysis, combination therapy analysis, source of business for recently treated patients, persistency and compliance analysis, product-level patient flowcharts
Product enhancement
Treatment Algorithms: Claims Data Analysis leverages Clarivate’s proprietary Real-World Data, which brings larger patient samples, broader payer coverage, and faster availability for more robust and timely analyses. Additionally, we include new patient demographic analyses: age, gender, ethnicity, and region.
